Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 11Genitourinary 7Gynecologic 3Dermatologic 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1CNS 1

Conditions

Melanoma 2Sarcoma 1

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Dactinomycin × Dermatologic × Clear all
NCT01323517 2018-05-15

Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
26 enrolled 11 charts
Dermatologic

Melanoma

NCT00004250 2013-01-16

Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or Leg That Cannot Be Removed By Surgery

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
35 enrolled
DermatologicSarcoma

Melanoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡